TABLE 3.
No | Study | Clearly stated aim | Inclusion of consecutive patients | Prospective collection of data | Endpoints appropriate to the aim of the study | Unbiased assessment of the study endpoint | Follow-up period appropriate to the aim of the study | Loss to follow up less than 5% | Prospective calculation of the study size | MINORS score |
---|---|---|---|---|---|---|---|---|---|---|
1 | Lin Y | 2 | 0 | 2 | 2 | 2 | 2 | 2 | 0 | 12 |
2 | Jennifer N. Brudno | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 16 |
3 | Hao S | 2 | 0 | 2 | 2 | 2 | 2 | 2 | 0 | 12 |
4 | Alsina M | 2 | 2 | 2 | 2 | 1 | 2 | 2 | 0 | 13 |
5 | Wan-Hong Zhao | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 0 | 14 |
6 | Sham Mailankody | 2 | 0 | 2 | 2 | 0 | 0 | 0 | 0 | 6 |
7 | Kumar SK | 2 | 2 | 2 | 2 | 2 | 0 | 2 | 0 | 12 |
8 | Sham Mailankody | 2 | 0 | 2 | 2 | 2 | 0 | 2 | 0 | 10 |
9 | Di Wang | 2 | 2 | 2 | 2 | 2 | 0 | 2 | 0 | 12 |
10 | Shwetha H. Manjunath | 2 | 2 | 2 | 2 | 0 | 2 | 2 | 0 | 12 |
11 | Damian J. Green | 2 | 0 | 2 | 2 | 2 | 0 | 2 | 0 | 10 |
12 | Jesus G Berdeja MD | 2 | 2 | 2 | 2 | 2 | 1 | 2 | 0 | 13 |
13 | Nikhil C. Munshi | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 0 | 14 |
14 | XiaoYuan, Zhang | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 16 |
15 | Juan Du | 2 | 2 | 2 | 1 | 2 | 2 | 2 | 2 | 15 |
16 | Xiaoyan Qu | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 0 | 14 |
17 | Chen W | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 0 | 14 |
18 | Costello CL | 2 | 2 | 2 | 1 | 1 | 2 | 2 | 0 | 12 |
19 | Frigault MJ | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 0 | 14 |
20 | Hu Y | 2 | 2 | 2 | 1 | 1 | 2 | 2 | 2 | 14 |
21 | Chunrui Li | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 16 |